

## Archived Editions (COVID-19 Genomics and Precision Public Health Weekly Update)

Published on 03/11/2021

### COVID-19 Genomics and Precision Public Health Weekly Update Content

- Pathogen and Human Genomics Studies
- Non-Genomics Precision Health Studies
- News, Reviews and Commentaries

#### Pathogen and Human Genomics Studies

- Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=862)  
RE Chen et al, Nature Medicine, March 4, 2021

As antibodies binding to spike receptor-binding domain and N-terminal domain demonstrate diminished neutralization potency in vitro against some emerging variants, updated mAb cocktails targeting highly conserved regions, enhancement of mAb potency or adjustments to the spike sequences of vaccines may be needed to prevent loss of protection in vivo.

- Persistent SARS-CoV-2 infection and increasing viral variants in children and young adults with impaired humoral immunity (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=863)  
Truong TT, et al. medRxiv, Mar 3, 2021.

"There is increasing concern that persistent infection of SARS-CoV-2 within immunocompromised hosts could serve as a reservoir for mutation accumulation and subsequent emergence of novel strains with the potential to evade immune responses...We describe three patients with acute lymphoblastic leukemia who were persistently positive for SARS-CoV-2 by real-time polymerase chain reaction. Viral viability from longitudinally-collected specimens was assessed. Whole-genome sequencing and serological studies were performed to measure viral evolution and evidence of immune escape. We found compelling evidence of ongoing replication and infectivity for up to 162 days from initial positive by subgenomic RNA, single-stranded RNA, and viral culture analysis."

- Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=864)  
Faria NR, et al. medRxiv, Mar 3, 2021.

"Cases of SARS-CoV-2 infection in Manaus, Brazil, resurged in late 2020, despite high levels of previous infection there. Through genome sequencing of viruses sampled in Manaus between November 2020 and January 2021, we identified the emergence and circulation of a novel SARS-CoV-2 variant of concern, lineage P.1, that acquired 17 mutations, including a trio in the spike protein (K417T, E484K and N501Y) associated with increased binding to the human ACE2 receptor...Using a two-category dynamical model that integrates genomic and mortality data, we estimate that P.1 may be 1.4-2.2 times more transmissible and 25-61% more likely to evade protective immunity elicited by previous infection with non-P.1 lineages."

- Cardiometabolic risk factors for COVID-19 susceptibility and severity: A Mendelian randomization analysis. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=872)  
Leong Aaron et al. PLoS medicine 2021 3 (3) e1003553

Epidemiological studies report associations of diverse cardiometabolic conditions including obesity with COVID-19 illness, but causality has not been established. Using mendelian randomization and UK biobank data, we found genetic evidence to support higher BMI as a causal risk factor for COVID-19 susceptibility and severity.

- Interferon antagonism by SARS-CoV-2: a functional study using reverse genetics (/PHGKB/phgHome.action?...

action=forward&dbsource=covUpdate&id=875)

S Schroeder et al, Lancet Microbe, March 4, 2021

- Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected persons (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=887)

AM Demonbreun et al, MEDRXIV, March 8, 2021

Previous COVID-19 diagnosis was associated with strong anti-spike RBD IgG and in vitro neutralizing responses after one vaccine dose. Persons seropositive for anti-spike RBD IgG in the absence of acute viral diagnostic testing, and those who were seronegative, required two doses to achieve equivalently high levels of IgG and neutralization activity. One mRNA vaccine dose is not sufficient to generate in vitro evidence of strong protection against COVID-19 among most persons previously infected with SARS-CoV-2, nor among seronegative persons.

- Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 (/PHGKB/phgHome.action?

action=forward&dbsource=covUpdate&id=888)

P Wang et al, Nature, March 8, 2021

We report that B.1.1.7 is refractory to neutralization by most mAbs to the N-terminal domain (NTD) of the spike and relatively resistant to a few mAbs to the receptor-binding domain (RBD). It is not more resistant to convalescent plasma or vaccinee sera. Findings on B.1.351 are more worrisome in that this variant is not only refractory to neutralization by most NTD mAbs but also by multiple individual mAbs to the receptor-binding motif on RBD, largely owing to an E484K mutation.

- Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein (/PHGKB/phgHome.action?

action=forward&dbsource=covUpdate&id=892)

H Tegally et al, Nature, March 9, 2021

We describe a new SARS-CoV-2 lineage (501Y.V2) characterized by 8t mutations in the spike protein, including 3 at important residues in the receptor-binding domain (K417N, E484K and N501Y) that may have functional significance<sup>3-5</sup>. This lineage was identified in South Africa after the first epidemic wave in a severely affected metropolitan area, Nelson Mandela Bay. This lineage spread rapidly, becoming dominant in the Eastern Cape, Western Cape and KwaZulu-Natal Provinces within weeks.

- SARS-CoV-2 within-host diversity and transmission (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=894)

SA Lythgoe et al, Science, March 9, 2021

We sequenced 1313 clinical samples from the UK. SARS-CoV-2 infections are characterized by low levels of within-host diversity when viral loads are high, and a bottleneck at transmission. Most variants are either lost, or occasionally fixed, at the point of transmission, with minimal persistence of shared diversity. Our results suggest that transmission-enhancing and/or immune-escape variants arise infrequently, but could spread rapidly if successfully transmitted.

- Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes (/PHGKB/phgHome.action?

action=forward&dbsource=covUpdate&id=895)

CM Saad-Roy et al, Science, March 9, 2021

We find that in the short-term, focusing on one dose generally decreases infections, but longer-term outcomes depend on this relative immune robustness. We explore 3 scenarios of selection and find that a one-dose policy may increase the potential for antigenic evolution under certain conditions of partial population immunity. We highlight the critical need to test viral loads and quantify immune responses after 1 vaccine dose, and to ramp up vaccination efforts around the world.

- Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=899)

X Deng et al, MEDRXIV, March 9, 2021

Our analyses revealed 2-fold increased B.1.427/B.1.429 viral shedding in vivo and increased L452R pseudovirus infection of cell cultures and lung organoids, albeit decreased relative to pseudoviruses carrying the N501Y mutation found in SARS-CoV-2 variants of concern (B.1.1.7, B.1.351, and P.1 lineages). Antibody neutralization assays showed 4.0 to 6.7-fold and 2.0-fold decreases in neutralizing titers from convalescent patients and vaccine recipients, respectively.

- Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2. (/PHGKB/phgHome.action?

action=forward&dbsource=covUpdate&id=902)

Baggen Jim et al. Nature genetics 2021 3

We performed genome-wide functional genetic screens with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and human coronavirus 229E. These screens uncovered virus-specific as well as shared host factors, including TMEM41B and PI3K type 3. SARS-CoV-2 requires the lysosomal protein TMEM106B to infect human cell lines and primary lung cells. TMEM106B overexpression enhanced SARS-CoV-2 infection as well as pseudovirus infection, suggesting a role in viral entry.

- Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study ([/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=903](#))  
R Challen et al, BMJ, March 10, 2021

54,906 matched pairs of participants who tested positive for SARS-CoV-2 in pillar 2 between 1 October 2020 and 29 January 2021, followed-up until 12 February 2021. The mortality hazard ratio associated with infection with VOC-202012/1 compared with infection with previously circulating variants was 1.64 in patients who tested positive for covid-19 in the community. In this comparatively low risk group, this represents an increase in deaths from 2.5 to 4.1 per 1000 detected cases.

- SARS-CoV-2 evolution in animals suggests mechanisms for rapid variant selection ([/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=904](#))  
Bashor L, et al. bioRxiv, Mar 9, 2021.
- Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies ([/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=908](#))  
DA Collier et al, Nature, March 11, 2021

Here we assessed immune responses following vaccination with mRNA-based vaccine BNT162b22. We measured neutralising antibody responses following first and second immunisations using pseudoviruses expressing the wild-type Spike protein or the 8 amino acid mutations found in the B.1.1.7 spike protein. The vaccine sera exhibited a broad range of neutralising titres against the wild-type pseudoviruses that were modestly reduced against B.1.1.7 variant.

## Non-Genomics Precision Health Studies

- Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies ([/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=862](#))  
RE Chen et al, Nature Medicine, March 4, 2021

As antibodies binding to spike receptor-binding domain and N-terminal domain demonstrate diminished neutralization potency in vitro against some emerging variants, updated mAb cocktails targeting highly conserved regions, enhancement of mAb potency or adjustments to the spike sequences of vaccines may be needed to prevent loss of protection in vivo.

- Persistent SARS-CoV-2 infection and increasing viral variants in children and young adults with impaired humoral immunity ([/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=863](#))  
Truong TT, et al. medRxiv, Mar 3, 2021.

"There is increasing concern that persistent infection of SARS-CoV-2 within immunocompromised hosts could serve as a reservoir for mutation accumulation and subsequent emergence of novel strains with the potential to evade immune responses....We describe three patients with acute lymphoblastic leukemia who were persistently positive for SARS-CoV-2 by real-time polymerase chain reaction. Viral viability from longitudinally-collected specimens was assessed. Whole-genome sequencing and serological studies were performed to measure viral evolution and evidence of immune escape. We found compelling evidence of ongoing replication and infectivity for up to 162 days from initial positive by subgenomic RNA, single-stranded RNA, and viral culture analysis."

- Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil ([/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=864](#))  
Faria NR, et al. medRxiv, Mar 3, 2021.

"Cases of SARS-CoV-2 infection in Manaus, Brazil, resurged in late 2020, despite high levels of previous infection there. Through genome sequencing of viruses sampled in Manaus between November 2020 and January 2021, we identified the emergence and circulation of a novel SARS-CoV-2 variant of concern, lineage P.1, that acquired 17 mutations, including a trio in the spike protein (K417T, E484K and N501Y) associated with increased binding to the human ACE2 receptor....Using a

two-category dynamical model that integrates genomic and mortality data, we estimate that P.1 may be 1.4-2.2 times more transmissible and 25-61% more likely to evade protective immunity elicited by previous infection with non-P.1 lineages."

- Cardiometabolic risk factors for COVID-19 susceptibility and severity: A Mendelian randomization analysis.

(/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=872)

Leong Aaron et al. PLoS medicine 2021 3 (3) e1003553

Epidemiological studies report associations of diverse cardiometabolic conditions including obesity with COVID-19 illness, but causality has not been established. Using mendelian randomization and UK biobank data, we found genetic evidence to support higher BMI as a causal risk factor for COVID-19 susceptibility and severity.

- Interferon antagonism by SARS-CoV-2: a functional study using reverse genetics (/PHGKB/phgHome.action?

action=forward&dbsource=covUpdate&id=875)

S Schroeder et al, Lancet Microbe, March 4, 2021

- Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected persons (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=887)

AM Demonbreun et al, MEDRXIV, March 8, 2021

Previous COVID-19 diagnosis was associated with strong anti-spike RBD IgG and in vitro neutralizing responses after one vaccine dose. Persons seropositive for anti-spike RBD IgG in the absence of acute viral diagnostic testing, and those who were seronegative, required two doses to achieve equivalently high levels of IgG and neutralization activity. One mRNA vaccine dose is not sufficient to generate in vitro evidence of strong protection against COVID-19 among most persons previously infected with SARS-CoV-2, nor among seronegative persons.

- Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 (/PHGKB/phgHome.action?

action=forward&dbsource=covUpdate&id=888)

P Wang et al, Nature, March 8, 2021

We report that B.1.1.7 is refractory to neutralization by most mAbs to the N-terminal domain (NTD) of the spike and relatively resistant to a few mAbs to the receptor-binding domain (RBD). It is not more resistant to convalescent plasma or vaccinee sera. Findings on B.1.351 are more worrisome in that this variant is not only refractory to neutralization by most NTD mAbs but also by multiple individual mAbs to the receptor-binding motif on RBD, largely owing to an E484K mutation.

- Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein (/PHGKB/phgHome.action?

action=forward&dbsource=covUpdate&id=892)

H Tegally et al, Nature, March 9, 2021

We describe a new SARS-CoV-2 lineage (501Y.V2) characterized by 8 mutations in the spike protein, including 3 at important residues in the receptor-binding domain (K417N, E484K and N501Y) that may have functional significance<sup>3-5</sup>. This lineage was identified in South Africa after the first epidemic wave in a severely affected metropolitan area, Nelson Mandela Bay. This lineage spread rapidly, becoming dominant in the Eastern Cape, Western Cape and KwaZulu-Natal Provinces within weeks.

- SARS-CoV-2 within-host diversity and transmission (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=894)

SA Lythgoe et al, Science, March 9, 2021

We sequenced 1313 clinical samples from the UK. SARS-CoV-2 infections are characterized by low levels of within-host diversity when viral loads are high, and a bottleneck at transmission. Most variants are either lost, or occasionally fixed, at the point of transmission, with minimal persistence of shared diversity. Our results suggest that transmission-enhancing and/or immune-escape variants arise infrequently, but could spread rapidly if successfully transmitted.

- Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes (/PHGKB/phgHome.action?

action=forward&dbsource=covUpdate&id=895)

CM Saad-Roy et al, Science, March 9, 2021

We find that in the short-term, focusing on one dose generally decreases infections, but longer-term outcomes depend on this relative immune robustness. We explore 3 scenarios of selection and find that a one-dose policy may increase the potential for antigenic evolution under certain conditions of partial population immunity. We highlight the critical need to test viral loads and quantify immune responses after 1 vaccine dose, and to ramp up vaccination efforts around the world.

- Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation ([/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=899](#))

X Deng et al, MEDRXIV, March 9, 2021

Our analyses revealed 2-fold increased B.1.427/B.1.429 viral shedding in vivo and increased L452R pseudovirus infection of cell cultures and lung organoids, albeit decreased relative to pseudoviruses carrying the N501Y mutation found in SARS-CoV-2 variants of concern (B.1.1.7, B.1.351, and P.1 lineages). Antibody neutralization assays showed 4.0 to 6.7-fold and 2.0-fold decreases in neutralizing titers from convalescent patients and vaccine recipients, respectively.

- Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2. ([/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=902](#))

Baggen Jim et al. Nature genetics 2021 3

We performed genome-wide functional genetic screens with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and human coronavirus 229E. These screens uncovered virus-specific as well as shared host factors, including TMEM41B and PI3K type 3. SARS-CoV-2 requires the lysosomal protein TMEM106B to infect human cell lines and primary lung cells. TMEM106B overexpression enhanced SARS-CoV-2 infection as well as pseudovirus infection, suggesting a role in viral entry.

- Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study ([/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=903](#))

R Challen et al, BMJ, March 10, 2021

54,906 matched pairs of participants who tested positive for SARS-CoV-2 in pillar 2 between 1 October 2020 and 29 January 2021, followed-up until 12 February 2021. The mortality hazard ratio associated with infection with VOC-202012/1 compared with infection with previously circulating variants was 1.64 in patients who tested positive for covid-19 in the community. In this comparatively low risk group, this represents an increase in deaths from 2.5 to 4.1 per 1000 detected cases.

- SARS-CoV-2 evolution in animals suggests mechanisms for rapid variant selection ([/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=904](#))

Bashor L, et al. bioRxiv, Mar 9, 2021.

- Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies ([/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=908](#))

DA Collier et al, Nature, March 11, 2021

Here we assessed immune responses following vaccination with mRNA-based vaccine BNT162b22. We measured neutralising antibody responses following first and second immunisations using pseudoviruses expressing the wild-type Spike protein or the 8 amino acid mutations found in the B.1.1.7 spike protein. The vaccine sera exhibited a broad range of neutralising titres against the wild-type pseudoviruses that were modestly reduced against B.1.1.7 variant.

## News, Reviews and Commentaries

- Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies ([/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=862](#))

RE Chen et al, Nature Medicine, March 4, 2021

As antibodies binding to spike receptor-binding domain and N-terminal domain demonstrate diminished neutralization potency in vitro against some emerging variants, updated mAb cocktails targeting highly conserved regions, enhancement of mAb potency or adjustments to the spike sequences of vaccines may be needed to prevent loss of protection in vivo.

- Persistent SARS-CoV-2 infection and increasing viral variants in children and young adults with impaired humoral immunity ([/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=863](#))

Truong TT, et al. medRxiv, Mar 3, 2021.

"There is increasing concern that persistent infection of SARS-CoV-2 within immunocompromised hosts could serve as a reservoir for mutation accumulation and subsequent emergence of novel strains with the potential to evade immune responses....We describe three patients with acute lymphoblastic leukemia who were persistently positive for SARS-CoV-2 by

real-time polymerase chain reaction. Viral viability from longitudinally-collected specimens was assessed. Whole-genome sequencing and serological studies were performed to measure viral evolution and evidence of immune escape. We found compelling evidence of ongoing replication and infectivity for up to 162 days from initial positive by subgenomic RNA, single-stranded RNA, and viral culture analysis."

- Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=864)

Faria NR, et al. medRxiv, Mar 3, 2021.

"Cases of SARS-CoV-2 infection in Manaus, Brazil, resurged in late 2020, despite high levels of previous infection there. Through genome sequencing of viruses sampled in Manaus between November 2020 and January 2021, we identified the emergence and circulation of a novel SARS-CoV-2 variant of concern, lineage P.1, that acquired 17 mutations, including a trio in the spike protein (K417T, E484K and N501Y) associated with increased binding to the human ACE2 receptor....Using a two-category dynamical model that integrates genomic and mortality data, we estimate that P.1 may be 1.4-2.2 times more transmissible and 25-61% more likely to evade protective immunity elicited by previous infection with non-P.1 lineages."

- Cardiometabolic risk factors for COVID-19 susceptibility and severity: A Mendelian randomization analysis. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=872)

Leong Aaron et al. PLoS medicine 2021 3 (3) e1003553

Epidemiological studies report associations of diverse cardiometabolic conditions including obesity with COVID-19 illness, but causality has not been established. Using mendelian randomization and UK biobank data, we found genetic evidence to support higher BMI as a causal risk factor for COVID-19 susceptibility and severity.

- Interferon antagonism by SARS-CoV-2: a functional study using reverse genetics (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=875)

S Schroeder et al, Lancet Microbe, March 4, 2021

- Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected persons (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=887)

AM Demonbreun et al, MEDRXIV, March 8, 2021

Previous COVID-19 diagnosis was associated with strong anti-spike RBD IgG and in vitro neutralizing responses after one vaccine dose. Persons seropositive for anti-spike RBD IgG in the absence of acute viral diagnostic testing, and those who were seronegative, required two doses to achieve equivalently high levels of IgG and neutralization activity. One mRNA vaccine dose is not sufficient to generate in vitro evidence of strong protection against COVID-19 among most persons previously infected with SARS-CoV-2, nor among seronegative persons.

- Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=888)

P Wang et al, Nature, March 8, 2021

We report that B.1.1.7 is refractory to neutralization by most mAbs to the N-terminal domain (NTD) of the spike and relatively resistant to a few mAbs to the receptor-binding domain (RBD). It is not more resistant to convalescent plasma or vaccinee sera. Findings on B.1.351 are more worrisome in that this variant is not only refractory to neutralization by most NTD mAbs but also by multiple individual mAbs to the receptor-binding motif on RBD, largely owing to an E484K mutation.

- Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=892)

H Tegally et al, Nature, March 9, 2021

We describe a new SARS-CoV-2 lineage (501Y.V2) characterized by 8t mutations in the spike protein, including 3 at important residues in the receptor-binding domain (K417N, E484K and N501Y) that may have functional significance<sup>3-5</sup>. This lineage was identified in South Africa after the first epidemic wave in a severely affected metropolitan area, Nelson Mandela Bay. This lineage spread rapidly, becoming dominant in the Eastern Cape, Western Cape and KwaZulu-Natal Provinces within weeks.

- SARS-CoV-2 within-host diversity and transmission (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=894)

SA Lythgoe et al, Science, March 9, 2021

We sequenced 1313 clinical samples from the UK. SARS-CoV-2 infections are characterized by low levels of within-host

diversity when viral loads are high, and a bottleneck at transmission. Most variants are either lost, or occasionally fixed, at the point of transmission, with minimal persistence of shared diversity. Our results suggest that transmission-enhancing and/or immune-escape variants arise infrequently, but could spread rapidly if successfully transmitted.

- Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=895)  
CM Saad-Roy et al, Science, March 9, 2021

We find that in the short-term, focusing on one dose generally decreases infections, but longer-term outcomes depend on this relative immune robustness. We explore 3 scenarios of selection and find that a one-dose policy may increase the potential for antigenic evolution under certain conditions of partial population immunity. We highlight the critical need to test viral loads and quantify immune responses after 1 vaccine dose, and to ramp up vaccination efforts around the world.

- Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=899)  
X Deng et al, MEDRXIV, March 9, 2021

Our analyses revealed 2-fold increased B.1.427/B.1.429 viral shedding in vivo and increased L452R pseudovirus infection of cell cultures and lung organoids, albeit decreased relative to pseudoviruses carrying the N501Y mutation found in SARS-CoV-2 variants of concern (B.1.1.7, B.1.351, and P.1 lineages). Antibody neutralization assays showed 4.0 to 6.7-fold and 2.0-fold decreases in neutralizing titers from convalescent patients and vaccine recipients, respectively.

- Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=902)  
Baggen Jim et al. Nature genetics 2021 3

We performed genome-wide functional genetic screens with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and human coronavirus 229E. These screens uncovered virus-specific as well as shared host factors, including TMEM41B and PI3K type 3. SARS-CoV-2 requires the lysosomal protein TMEM106B to infect human cell lines and primary lung cells. TMEM106B overexpression enhanced SARS-CoV-2 infection as well as pseudovirus infection, suggesting a role in viral entry.

- Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=903)  
R Challen et al, BMJ, March 10, 2021

54,906 matched pairs of participants who tested positive for SARS-CoV-2 in pillar 2 between 1 October 2020 and 29 January 2021, followed-up until 12 February 2021. The mortality hazard ratio associated with infection with VOC-202012/1 compared with infection with previously circulating variants was 1.64 in patients who tested positive for covid-19 in the community. In this comparatively low risk group, this represents an increase in deaths from 2.5 to 4.1 per 1000 detected cases.

- SARS-CoV-2 evolution in animals suggests mechanisms for rapid variant selection (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=904)  
Bashor L, et al. bioRxiv, Mar 9, 2021.

- Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=908)  
DA Collier et al, Nature, March 11, 2021

Here we assessed immune responses following vaccination with mRNA-based vaccine BNT162b22. We measured neutralising antibody responses following first and second immunisations using pseudoviruses expressing the wild-type Spike protein or the 8 amino acid mutations found in the B.1.1.7 spike protein. The vaccine sera exhibited a broad range of neutralising titres against the wild-type pseudoviruses that were modestly reduced against B.1.1.7 variant.

**Disclaimer:** Articles listed in COVID-19 Genomics and Precision Public Health Weekly Update are selected by the CDC Office of Public Health Genomics to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for

*informational purposes and do not imply endorsement by CDC or DHHS.*

---

Page last reviewed: Oct 1, 2020

Page last updated: Mar 30, 2021

Content source: Office of Genomics and Precision Public Health (<http://www.cdc.gov/genomics/>), CDC Office of Science (<https://www.cdc.gov/od/science/index.htm>)